Archiwum hase³
multimodality therapy | Regulatory T cells {Tregs} | Myeloid-derived suppressor cells {MDSC} | Mmantle cell lymphoma {MCL} | Autologous stem cell transplantation {ASCT} | T-cell infiltrating lymphocytes {TIL} | Dental Pulp Stem Cells {DPSC} | Stem Ce lls from Human Exfoliated Deciduous teeth {SHED} | Neuron specific enolase {NSE} | lactose operon | area under the curve {AUC} | non-receptor tyrosine kinase | Prokaryotic expression system | Multiple Cloning Sites {MCS} | origin of replication {ori} | nuclear polyhedrosis virus {NPV} | Molecularly imprinted polymers {MIPs} | Chronic allograft nephropathy {CAN} | metaphyseal | Spondylo-epi-metaphyseal dysplasias {SEMD} | Hepatosplenic gamma - delta cell lymphoma | Angioimmunoblastic Lymphadenopathy with Dysproteinemia {AILD} | primary myxedema | membrane glycoprotein | angioimmunoblastic lymphoma | cold ischemia time | Panel reactive antibody {PRA} | organ donation | fatal acute poisoning | Cerebrovascular accident {CVA} | Hemolytic – Uremic Syndrome | thrombotic thrombocytopenic purpura {TTP} | Antibody-mediated renal allograft rejection | Methicyllin-resistant Staphylococcus epidermidis {MRSE} | tubular atrophy{TA} | polyoma virus associated nephropathy {PVAN} | subclinical acute rejection {SCAR} | anti-body mediated rejection {ABMR} | Expanded criteria donor {ECD} | Deceased-donor score {DDS} | cadaveric donor | Donor specific antibodies {DSA} | Acute rejection episode {ARE} | mixed lymphocyte reaction {MLR} | Cardio-renal syndrome | Cold ischemia time {CIT} | Donor after cardiac death {DCD} | Warm ischemic time {WIT} | Ischemia-reperfusion injury {IRI} | Posttransplant diabetes mellitus {PTDM} | fasting plasma glucose {FPG} | acute metabolic decompensation | hypertriglyceridemia | low-molecular heparin | Common Toxicity Criteria {CTC} | blood urea nitrogen {BUN} | Hemolytic uremic syndrom {HUS} | Glucocorticoid response element {GRE} | Rituxymab associated lung injury {RALI } | End-stage renal disease {ESRD} | Direct antiglobulin test | collagen-induced arthritis {CIA} | Supercritical Fluid Chromatography {SFC} | site- directed mutagenesis | site- specific mutagenesis | chronic inflammatory demyelinating polyneuropathy {CIDP} | Multifocal motor neuropathy {MMN} | POEMS syndrome {POEMS} | lymphocyte-activation gene 3 {LAG-3} | Glia-derived neurothrophic factor {GDNF} | cysteine rich domain {CRD} | distribution half-life | distribution half-life | Primary immunodeficiency disorder {PID} | anorexia nervosa | brain-derived neurotrophic factor {BDNF} | neuropathic pain | Lymphocyte Activation Gene-3 {LAG-3} | Hydrophobic Interaction Chromatography {HIC} | solid tumor | Human Papilloma Viruse (HPV), | Kaposi's Herpes Sarcoma Virus {KHSV} | tumor angiogenesis | antigen presentation pathway | respiratory syncytial virus | Thrombin activatable fibrinolysis inhibitor {TAFI} | Haemorrhage diathesis | Tissue plasminogen activator {tPa) | Atherothrombosis | anti-cyclic citrullinated peptide antibodies (anti-CCP) | rheumatoid facto | Green fluorescent protein }GFP} | Tumor necrosis factor related - apoptosis inducing ligand {TRAIL} | Death inducing signaling complex {DISC} | AIDS – Related Complex {ARC} | distribution at steady state {Vss} | attenuated strain of virus | escape mutants | Pseudorabies virus | plasma kallikrein | Aujeszky's disease | mouse mammary tumor virus {MMTV} | Rous sarcoma virus | Cardiopulmonary bypass {CPB} | large unilameller vesicles {LUV} | multivesicular vesicles {MUV} | Apical ballooning syndrome {APS} | stress-induced cardiomyopathy | stunned myocardium | hibernating myocardium | neurotrophin {NT} | Peripheral arterial occlusive disease {PAOD} | sternotomy | cold atmospheric plasma {CAP} | Wounds-at-Risk Score {WAR} | Multi-drug resistance {MDR} | Explorative laparotomy (ex-lap) | skeletal drug delivery system | Peyer's Patch | bacterin | hypocretins | sleep disorders | autoimmunological diseases | Xenopus laevis | Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes {MELAS} | Myoclonic epilepsy and ragged red fibres {MERRF} | Chronic progressive external ophtalmoplegia {CPEO} | Leber´s hereditary optic neuropaty {LHON} | Kearns-Sayre syndrome {KSS} | Pearson pancreas-marrow syndrome {PPMS} | neuronal activity-regulated pentraxin | stress-activated mitogen kinases {SAPK} | dorsal and median raphae nuclei {DR} | tuberomamillary nucleus {TMN} | suprachiasmatic nuclei {SCN} | intergeniculate leaflet {IGL} | Arvicanthis niloticus | Rattus norvegicus | Multiple myeloma | New drugs | overactive bladder | smouldering multiple myeloma {SMM} | immunoglobulin heavy chain/ light chains analysis {HLC} | Renal insuficiency | Calcium, renal insuffciency, anemia, bone lesions {CRAB} | Asymptomatic multiple myeloma {AMM} | International Myeloma Working Group {IMWG} | International Staging System {ISS} | stringent complete remission {sCR} | very good partial remission {VGPR} | partial remission {PR} | progressive disease {PD} | interstitial cystitis | 1. relapse from CR | overall survival {OS} | autologous stem cell transplantation {autoSCT} | graft versus myeloma {GvM} | reduced intensity conditioning allogeneic stem cel transplantation {RIC-alloSCT} | high-dose therapy {HDT} | allele-specific oligonucleotide {ASO} | Matched sibling donor {MSD} | European Myeloma Network {EMN} | chemiotherapy-induced neuropathy {CINP} | erytropoesis-stimulating agents {ESA} | light-chain amyloidosis | free light chain {FLC} | high dose melphalan {HDMel} | stem cell transplantation {SCT} | Monoclonal Immunoglobulin Deposition Diseases {MIDD} | Light Chain Deposition Disease {LCDD} | Heavy Chain Deposition Disease {HCDD} | Light and Heavy Chain Deposition Disease {LHCDD} | Waldenström macroglobulinamia {WM} | lymphoplasmocytic lymphoma {LPL} | mantle cell lymphoma {MCL} | fluorescence in situ hybridization {FISH} | serum viscosity {SV} | International Prognostic Staging System for Waldenström's Makroglobulinemia {IPSSWM} | marginal zone lymphoma {MZL} | allogeneic hematopoietic stem cell transplantation {alloSCT} | Acute tubular necrosis {ATN} | Ascending reticular activating system {ARAS} | central nervous system {CNS} | complete remission {CR} | diagnosis | locus coeruleus {LC} | low molecular weight heparin {LMWH} | Matched Unrelated Donor {MUD} | mitogen-activated protein kinases {MAPK} | Monoclonal gammapathy of undetermined significance {MGUS} | narcolepsy | plasma cell myeloma | Related Organ or Tissue Impairment {ROTI} | splenic marginal zone lymphoma {SMZL} | stable disease {SD} | vascular endothelial growth factor {VEGF} | ventrolateral preoptic nucleus {VLPO} | Superior Labrum Anterior Posterior {SLAB} | Humeral shaft | sternoclavicular joint |
Poprzednia 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 Nastêpna
